BJMO - 2022, issue Special, may 2022
A. Dekker MD, T. Feys MBA, MSc
About 15% of patients with localised prostate cancer (PCa) are identified as having a high risk for disease recurrence and these patients account for the vast majority of PCa deaths. To date, however, the optimal treatment for patients with high-risk, localized PCa remains controversial. While it is important to offer these patients an effective treatment, this treatment should not come with excessive side effects or impact the patient’s quality of life (QoL).1 During a session at the 2022 BMUC meeting, the different treatment options for these patients were discussed from the perspective of the surgeon, the medical oncologist and the radiation oncologist.
Read moreBJMO - 2022, issue Special, may 2022
A. Dekker MD, T. Feys MBA, MSc
What is the role of the patient in the management of prostate cancer? During BMUC 2022, André Deschamps, prostate cancer (PCa) patient and Chairman of Europa UOMO aimed to answer this question. In his lecture, he discussed the effect of PCa and its treatment on the daily life of patients and addressed some of the barriers and gaps that hamper a closer involvement of patients in the treatment decision process. 1
Read moreBJMO - 2022, issue Special, may 2022
T. Feys MBA, MSc
The second day of the 2022 annual BMUC meeting kicked off with a session addressing three hot topics in the field of kidney cancer. In a first lecture, Prof. Dr. Toni Choueiri (Dana Farber Cancer Institute, Boston, MA, USA) discussed the management of patients with non-clear cell renal cell carcinoma (RCC). Subsequently, Dr. Marco Gizzi (GHdC, Charleroi) turned the attention to the adjuvant treatment of patients with RCC after which he gave an overview of new molecules for patients with metastatic RCC. Dr. Stephanie Kroeze (Universitätsspital Zürich, Zürich, Switzerland) closed the RCC session with a presentation on how to combine radiotherapy with systemic therapy in this setting.
Read moreBJMO - 2022, issue Special, may 2022
A. Enguita PhD, T. Feys MBA, MSc
In line with the tradition, the BMUC scientific committee asked a urologist, a radiation oncologist, and a medical oncologist to summarise the top stories presented during the large urology and oncology meetings of the past year.
Read more
Top
